Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development

This article was originally published in PharmAsia News

Executive Summary

BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development

You may also be interested in...



China FDA Set To Greenlight First Domestic Lymphoma Drug

On the verge of obtaining its first new drug approval from the China FDA to treat a rare cancer type, Chinese domestic biotech ChipScreen is poised to benefit from an increasingly confident regulatory agency.

Reverse Innovation In China: An Interview With HUYA CEO Mireille Gillings

Eight years ago, HUYA’s CEO Mireille Gillings began screening compounds developed in China to bring them to global markets. Nowadays, the company says it has a database with more than 12,000 compounds and 2,000 biomarkers from China.

Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference

BEIJING - With China's government poised to invest substantial funds in coming years to encourage innovative drug development, China is quickly becoming a favorite R&D destination for multinational pharmas, but both public and private players are still grappling with how to boost R&D productivity

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel